Endocrinology
| Dual incretin receptor agonists
Endocrinology
Dual incretin receptor agonists

Dual Incretin Receptor Agonists: How Far Have We Gone with “Twincretins"?

book_2 Source: ENDO 2022 - Oral Session
calendar_today Published on Medfyle: June 2022
import_contacts 7 min
headphones 4 min

In this medfyle

Dual incretin receptor agonists are changing the goals of therapy for type 2 diabetes and weight loss.

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Expert commentary

Vivian Fonseca, MD

Professor of Medicine and Pharmacology 
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes 
Chief, Section of Endocrinology
Tulane University Health Sciences Center 
New Orleans, LA, USA

About this Medfyle
Read more arrow_downward Hide arrow_upward

This is a highlights summary of an oral session given at the ENDO 2022 Annual Conference and presented by:

Julio Rosenstock, MD
Dallas Diabetes Research Center at Medical City
University of Texas Southwestern Medical Center
Dallas, TX, USA

The content is produced by Infomedica, the official reporting partner of ENDO 2022. 

The presenting authors of the original session had no part in the creation of this conference highlights summary.

In addition, an expert commentary on the topic has been provided by:

Vivian Fonseca, MD, FRCP
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center


Feedback